{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:45:51Z","timestamp":1792147551164,"version":"4.4.0"},"reference-count":43,"publisher":"National Center for Global Health and Medicine (JST)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["GHM"],"published-print":{"date-parts":[[2025,4,30]]},"DOI":"10.35772\/ghm.2025.01004","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:07:17Z","timestamp":1744150037000},"page":"151-160","source":"Crossref","is-referenced-by-count":5,"title":["Large-scale screening of SARS-CoV-2 variants in Tokyo, Japan: A 3-year and 9-month longitudinal survey"],"prefix":"10.35772","volume":"7","author":[{"given":"Junko S.","family":"Takeuchi","sequence":"first","affiliation":[{"name":"Biorepository and Research Laboratory, Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Laboratory Testing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Fukano","sequence":"additional","affiliation":[{"name":"Biorepository and Research Laboratory, Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Kamikawa","sequence":"additional","affiliation":[{"name":"Biorepository and Research Laboratory, Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Hatano","sequence":"additional","affiliation":[{"name":"Biorepository and Research Laboratory, Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakino","family":"Takayanagi-Nishisako","sequence":"additional","affiliation":[{"name":"Biorepository and Research Laboratory, Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Motohashi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Testing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Takamatsu","sequence":"additional","affiliation":[{"name":"Department of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[{"name":"Department of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moto","family":"Kimura","sequence":"additional","affiliation":[{"name":"Biorepository and Research Laboratory, Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21485","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Wu F, Zhao S, Yu B<i>, et al.<\/i> A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579:265-269.","DOI":"10.1038\/s41586-020-2008-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Volz E, Mishra S, Chand M, <i>e t a l .<\/i> Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021; 593:266-269.","DOI":"10.1038\/s41586-021-03470-x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mlcochova P, Kemp SA, Dhar MS, <i>et al.<\/i> SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021; 599:114-119.","DOI":"10.1038\/s41586-021-03944-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Viana R, Moyo S, Amoako DG, <i>et al.<\/i> Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022; 603:679-686.","DOI":"10.1038\/s41586-022-04411-y"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, Wilairatana P. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2? Biomed Pharmacother. 2022; 154:113522.","DOI":"10.1016\/j.biopha.2022.113522"},{"key":"6","unstructured":"6. Haileamlak A. The impact of COVID-19 on health and health systems. Ethiop J Health Sci. 2021; 31:1073-1074."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fatani M, Shamayleh A, Alshraideh H. Assessing the disruption impact on healthcare delivery. J Prim Care Community Health. 2024; 15:21501319241260351.","DOI":"10.1177\/21501319241260351"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, Consortium C-GU, Peacock SJ, Barclay WS, de Silva TI, Towers GJ, Robertson DL. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023; 21:162-177.","DOI":"10.1038\/s41579-022-00841-7"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ferdinand AS, Kelaher M, Lane CR, da Silva AG, Sherry NL, Ballard SA, Andersson P, Hoang T, Denholm JT, Easton M, Howden BP, Williamson DA. An implementation science approach to evaluating pathogen whole genome sequencing in public health. Genome Med. 2021; 13:121.","DOI":"10.1186\/s13073-021-00934-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hayakawa K, Kutsuna S, Kawamata T, et al. SARSCoV-2 infection among returnees on charter flights to Japan from Hubei, China: A report from National Center for Global Health and Medicine. Glob Health Med. 2020; 2:107-111.","DOI":"10.35772\/ghm.2020.01036"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tsuboi M, Hachiya M, Noda S, Iso H, Umeda T. Epidemiology and quarantine measures during COVID-19 outbreak on the cruise ship Diamond Princess docked at Yokohama, Japan in 2020: A descriptive analysis. Glob Health Med. 2020; 2:102-106.","DOI":"10.35772\/ghm.2020.01037"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ode H, Nakata Y, Nagashima M, <i>et al.<\/i> Molecular epidemiological features of SARS-CoV-2 in Japan, 2020-1. Virus Evol. 2022; 8:veac034.","DOI":"10.1093\/ve\/veac034"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ko K, Takahashi K, Nagashima S, <i>et al.<\/i> Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan. Sci Rep. 2022; 12:2419.","DOI":"10.1038\/s41598-022-04952-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tzou PL, Tao K, Pond SLK, Shafer RW. Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons. PLoS One. 2022; 17:e0261045.","DOI":"10.1371\/journal.pone.0261045"},{"key":"15","unstructured":"15. GISAID. The Global Initiative on Sharing All Influenza Data (GISAID) EpiCoV database. <i>https:\/\/gisaid.org<\/i> (accessed January 9, 2025)."},{"key":"16","unstructured":"16. World Health Organization. Tracking SARS-CoV-2 variants. <i>https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants\/<\/i> (accessed March 3, 2025)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nakagawa S, Katayama T, Jin L, Wu J, Kryukov K, Oyachi R, Takeuchi JS, Fujisawa T, Asano S, Komatsu M, Onami JI, Abe T, Arita M. SARS-CoV-2 HaploGraph: visualization of SARS-CoV-2 haplotype spread in Japan. Genes Genet Syst. 2023; 98:221-237.","DOI":"10.1266\/ggs.23-00085"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kitahara K, Nishikawa Y, Yokoyama H, Kikuchi Y, Sakoi M. An overview of the reclassification of COVID-19 of the Infectious Diseases Control Law in Japan. Glob Health Med. 2023; 5:70-74.","DOI":"10.35772\/ghm.2023.01023"},{"key":"19","unstructured":"19. The Ministry of Health, Labour and Welfare. Response to COVID-19 after the classification change. <i>https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000164708_00079.html<\/i> (accessed March 3, 2025)."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Arima Y, Takahashi T, Kasamatsu A, Arashiro T, Kobayashi Y, Otsuka M, Takahara O, Shimbashi R, Komase K, Kamigaki T, Suzuki M. Sentinel Surveillance of COVID-19: The Importance of Epidemiologic Concepts and Reasoning. J Epidemiol. 2025; 35:106-107.","DOI":"10.2188\/jea.JE20240200"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lee B, Quadeer AA, Sohail MS, Finney E, Ahmed SF, McKay MR, Barton JP. Inferring effects of mutations on SARS-CoV-2 transmission from genomic surveillance data. Nat Commun. 2025; 16:441.","DOI":"10.1038\/s41467-024-55593-0"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hay JA, Kennedy-Shaffer L, Kanjilal S, Lennon NJ, Gabriel SB, Lipsitch M, Mina MJ. Estimating epidemiologic dynamics from cross-sectional viral load distributions. Science. 2021; 373:eabh0635.","DOI":"10.1126\/science.abh0635"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis. 2022; 22:e311-e326.","DOI":"10.1016\/S1473-3099(22)00311-5"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Halfmann PJ, Kawaoka Y. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2023; 388:89-91.","DOI":"10.1056\/NEJMc2214302"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE, Jr., Purcell LA, Kawaoka Y, Corti D, Fremont DH, Diamond MS. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022; 28:490-495.","DOI":"10.1038\/s41591-021-01678-y"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Okumura N, Saito S, Takamatsu Y, Takeuchi JS, Asai Y, Sanada M, Iwamoto N, Maeda K, Mitsuya H, Ohmagari N. Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination. J Infect Chemother. 2022; 28:1704-1706.","DOI":"10.1016\/j.jiac.2022.08.026"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Okumura N, Tsuzuki S, Saito S, Hattori SI, Takeuchi JS, Saito T, Ujiie M, Hojo M, Iwamoto N, Sugiura W, Mitsuya H, Ohmagari N. Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan. J Infect Chemother. 2022; 28:1340-1343.","DOI":"10.1016\/j.jiac.2022.04.018"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Okumura N, Tsuzuki S, Saito S, Saito T, Takasago S, Hojo M, Iwamoto N, Ohmagari N. The first eleven cases of SARS-CoV-2 Omicron variant infection in Japan: A focus on viral dynamics. Glob Health Med. 2022; 4:133-136.","DOI":"10.35772\/ghm.2021.01124"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Yamamoto S, Matsuda K, Maeda K, Oshiro Y, Inamura N, Mizoue T, Konishi M, Takeuchi JS, Horii K, Ozeki M, Sugiyama H, Mitsuya H, Sugiura W, Ohmagari N. Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2. BMC Infect Dis. 2023; 23:282.","DOI":"10.1186\/s12879-023-08272-2"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Yamamoto S, Matsuda K, Maeda K, <i>et al.<\/i> Protection of Omicron bivalent vaccine, previous infection, and their induced neutralizing antibodies against symptomatic infection with Omicron XBB.1.16 and EG.5.1. Open Forum Infect Dis. 2024; 11:ofae519.","DOI":"10.1093\/ofid\/ofae519"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Yamamoto S, Matsuda K, Maeda K, <i>et al.<\/i> Preinfection neutralizing antibodies, Omicron BA.5 breakthrough infection, and long COVID: A propensity score-matched analysis. J Infect Dis. 2023; 228:1652-1661.","DOI":"10.1093\/infdis\/jiad317"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Iwasaki M, Hashimoto M, Takeuchi JS, Kusaba Y, Kimura M, Terada-Hirashima J, Sugiura W, Hojo M. Relapse of COVID-19 and viral evolution in a patient with good syndrome: A case report. Cureus. 2024; 16:e52592.","DOI":"10.7759\/cureus.52592"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Saito A, Irie T, Suzuki R, <i>et al<\/i>. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature. 2022; 602:300-306","DOI":"10.1038\/s41586-021-04266-9"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Ward IL, Bermingham C, Ayoubkhani D, Gethings OJ, Pouwels KB, Yates T, Khunti K, Hippisley-Cox J, Banerjee A, Walker AS, Nafilyan V. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. BMJ. 2022; 378:e070695.","DOI":"10.1136\/bmj-2022-070695"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Alhamlan FS, Al-Qahtani AA. SARS-CoV-2 Variants: Genetic insights, epidemiological tracking, and implications for vaccine strategies. Int J Mol Sci. 2025; 26:1263.","DOI":"10.3390\/ijms26031263"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Kayano T, Ko Y, Otani K, Kobayashi T, Suzuki M, Nishiura H. Evaluating the COVID-19 vaccination program in Japan, 2021 using the counterfactual reproduction number. Sci Rep. 2023; 13:17762.","DOI":"10.1038\/s41598-023-44942-6"},{"key":"37","unstructured":"37. The Ministry of Health, Labor and Welfare. Number of doses to receive the new corona vaccine. <i>https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/kenkou\/kekkaku-kansenshou\/yobou-sesshu\/syukeihou_00002.html<\/i> (accessed March 3, 2025). (in Japanese)"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Mimura W, Ishiguro C, Maeda M, Murata F, Fukuda H. Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. Int J Infect Dis. 2022; 125:58-60.","DOI":"10.1016\/j.ijid.2022.10.001"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Song S, Madewell ZJ, Liu M, Miao Y, Xiang S, Huo Y, Sarkar S, Chowdhury A, Longini IM, Jr., Yang Y. A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants. Vaccine. 2024; 42:3389-3396.","DOI":"10.1016\/j.vaccine.2024.04.049"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Happle C, Hoffmann M, Kempf A, Nehlmeier I, Stankov MV, Calderon Hampel N, Witte T, Pohlmann S, Behrens GMN, Dopfer-Jablonka A. Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination. Lancet Infect Dis. 2024; 24:e674-e676.","DOI":"10.1016\/S1473-3099(24)00603-0"},{"key":"41","unstructured":"41. World Health Organization. <i>https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing---5-may-2023<\/i> (accessed March 4, 2025)."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Gangavarapu K, Latif AA, Mullen JL, <i>et al.<\/i> Outbreak.info genomic reports: Scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. Nat Methods. 2023; 20:512-522.","DOI":"10.1038\/s41592-023-01769-3"},{"key":"43","unstructured":"43. The Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19 infections. <i>https:\/\/covid19.mhlw.go.jp\/en\/<\/i> (accessed March 3, 2025)."}],"container-title":["Global Health &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/7\/2\/7_2025.01004\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:42:08Z","timestamp":1746852128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/7\/2\/7_2025.01004\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.35772\/ghm.2025.01004","relation":{},"ISSN":["2434-9186","2434-9194"],"issn-type":[{"value":"2434-9186","type":"print"},{"value":"2434-9194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"article-number":"2025.01004"}}